COMPARISON
Two premium headphones with neuroscience hardware hidden inside. One reads your brain and reports back. The other reads your nervous system and acts on it.
Loading…
Continue Reading
Related articles from the knowledge base
COMPARISON
Two Different Answers to the Same Question
11 min read
COMPARISON
Three Neurostimulation Devices. Three Completely Different Jobs.
12 min read
TECHNOLOGY CHOICE
Why We Chose tDCS Over Every Other Brain Technology.
12 min read
TECHNOLOGY
What Is Closed-Loop tDCS, and Why It Changes Everything
12 min read
FREQUENTLY ASKED
Neither is better in the abstract, because they do different jobs. The MW75 Neuro LT is the stronger choice for validated brain tracking you can buy and use today. Sychedelic is the stronger choice if you want a device that reads your physiological state and actively shifts it inside a single session, with the caveats that it ships in December 2026 and that stimulation response varies between individuals.
Neurable measures. Twelve EEG channels report on your focus and fatigue, and you decide what to do about it. Sychedelic modulates. It reads heart-rate variability through an optical sensor, plays adaptive audio to settle your nervous system, then delivers a gated 20-minute course of tDCS to the prefrontal cortex. One tells you what is happening. The other tries to change it.
No. Both are EEG-tracking devices only. Neurable states in its own FAQ that the headphones do not stimulate brain activity or inject electrical signals into your brain, in the same way a smartwatch measures your heart rate without trying to change it. For a stimulation-based closed-loop approach, Sychedelic is the relevant product.
Sychedelic is available to pre-order at a $549 founding price against $799 retail, following a $3.5 million seed round and a CDSCO Manufacturing License in India. Units are scheduled to ship in December 2026, and the reservation is fully refundable. The Neurable MW75 Neuro LT, by comparison, is shipping now at $499 in the US and Canada with a 14-day return window.
Neurable has the longer public track record on sensing: Mayo Clinic testing of its Brain Break feature, validation work with the US Air Force Research Laboratory, and roughly a century of EEG science behind the method itself. Sychedelic's advantage is regulatory: a CDSCO Manufacturing License, independent ISO 10993 biocompatibility and IEC 60601-1-2 electromagnetic safety testing, a filed PCT patent, and a scientific advisory board anchored by Giuseppina Pilloni of NYU Grossman School of Medicine. Those certifications cover safety and biocompatibility, not proven efficacy.
Yes, in effect. Ria Rustagi and Bhavya Madan founded the company in 2020 as Neuphony, building EEG neurofeedback headbands, and after seven years in that field, they pivoted to Sychedelic to build closed-loop neuromodulation instead. Same founders, same deep-tech team, a fundamentally different product philosophy: intervention rather than measurement.
At its stated settings of up to 2 mA in 20-minute sessions, tDCS is considered a mild, non-invasive form of stimulation, and the largest safety review of the literature found no serious adverse events across more than 33,200 conventional sessions. The common effects are transient tingling or slight redness at the electrode site. It is not FDA-cleared. Anyone pregnant, has a seizure history, uses an implanted device, has an active skin condition at the electrode site, or is under 18 should follow the contraindications and consult a clinician.
Sychedelic holds a CDSCO Manufacturing License (No. MFG/MD/2026/000135, Telangana Drugs Control Administration), valid through 2031, classifying it as a Class B medical device in India. It has passed three independent, GLP-certified and OECD-compliant biocompatibility studies through GLR Laboratories, with non-cytotoxic, non-irritant and non-sensitising results under ISO 10993-5, -23 and -10, plus electromagnetic safety testing through NABL-accredited Tata Advanced Systems under IEC 60601-1-2 Edition 4.1 and IEC 61000-4-2. A PCT patent application covering its closed-loop neuromodulation method was filed with the Indian Patent Office in February 2026. None of this is FDA clearance, and it doesn't prove the stimulation works better — it confirms the device is safe to wear and won't interfere with nearby electronics.
Because it is an intervention device, not a recorder. Its founders spent seven years building consumer EEG hardware and concluded that for a system that has to respond inside a session, speed, wearability and signal stability matter more than maximum recording fidelity. PPG-derived HRV is the best-researched non-invasive readiness marker available, and it holds up during a normal working day, which is what a closed loop needs to act.
The stimulation phase runs for 20 minutes on a hardware-controlled timer that the app cannot extend, and it only unlocks once your physiological readings show a genuine shift out of a stressed state. The protocol is designed to open a window of roughly 90 minutes of sharper focus afterwards. The general principle that tDCS effects can outlast the stimulation itself is supported by research; the specific duration for this device is a design target rather than a peer-reviewed result, so treat your own experience as the test.
No. Neither is positioned as a diagnostic tool, and neither should be used as one. Both companies frame their products around focus, stress and everyday cognitive performance rather than clinical diagnosis. If you suspect an underlying condition, speak to a qualified professional.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.